000			03083cam a2200349 a 4500
003			EG-GiCUC
005			20250223032810.0
008			210904s2021 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.08.09.M.Sc.2021.Na.P
100	0		_aNada Abdelsalam Abdelsabour
245	1	0	_aPharmacological study on the potential antineoplastic effects of thymoquinone and/or ellagic acid on HepG2 cells / _cNada Abdelsalam Abdelsabour ; Supervised Sanaa A. Kenawy , Gouda K. Helal , Nada A. Sallam
246	1	5	_aدراسة دوائية على الآثار المضادة للاورام المحتملة للثيموكوينون وحمض ايلاجيك منفردين أو مجتمعين على خلايا هيب جى- 2
260			_aCairo : _bNada Abdelsalam Abdelsabour , _c2021
300			_a107 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology
520			_aIn the 21st century, cancer is considered a major cause of death, specifically liver cancer hepatocellular carcinoma (HCC), which is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer death worldwide in 2018. Sorafenib (SF) was recommended as the first-line treatment for advanced HCC as it is a small molecule target therapy but although it is an attractive and approved treatment for HCC but still needs researches to avoid its side effects. Therefore, the present study was constructed in order to explore the potential anti-cancer activity of a novel combination of plant-derived natural products consisting of thymoquinone (TQ) and Ellagic acid (EA) against HCC on Hep-G2 cells, comparing their effects to a standard drug SF and investigating any synergism between each of them and SF, in addition to investigating the underlying mechanisms for such modulation with emphasis on proliferation and apoptosis. The effect of SF, TQ, and EA were evaluated separately and in combination on HepG2. Cell viability, MAPK, AKT, GPC-3, and GSK3Ý activities. Moreover; PSTAT-3, VEGF, MMP-9, caspase-3, and Bcl2/BAX ratio, as well as NF-mB, TNF-Ü, and IL-6 were measured. Thymoquinone and ellagic acid combination showed significant cell inhibition, affecting all indicators of cell proliferation and angiogenesis in results near to SF results, in the same way, the addition of EA to SF increased its effectiveness. All these results give promising combinations to increase the effectiveness and by default decrease the side effects of SF or use TQ and EA combination instead of SF alone
530			_aIssued also as CD
653		4	_aEllagic acid (EA)
653		4	_aHepatocellular carcinoma (HCC)
653		4	_aSorafenib (SF)
700	0		_aGouda K. Helal , _eSupervisor
700	0		_aNada A. Sallam , _eSupervisor
700	0		_aSanaa A. Kenawy , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c81964 _d81964